Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis

Table 1 Patient demographics

Ref.	Type of study	Total No. of patients	Age mean or median in years		Ivabradine + beta blocker (n)	Beta blocker alone (n)	Follow up time (mean/median) months	Mean baseline HR	NYHA class III - IV %		Coronary artery disease n (%)	Mean baseline ejection fraction	Atrial fibrillation	Beta blockers
			Ivabradine + beta blocker	Beta blocker alone					Ivabradine + beta blocker	Beta blocker alone				Ivabradine + beta blocker	Beta blocker alone
ETHIC-AHF[23] 2016	RCT	71	66 (15)	68 (12)	33	38	4	88	93	97	5 (10)	30%	NA	88	97
Bagriy et al[21] 2015	Prospective non-randomized	69	63 (12)	62 (11)	33	36	5	83	59	58	39 (57)	37%	NA	100	100
CARVIVA HF[20] 2011	RCT	80	67 (9)	67 (10)	42	38	3	78	50	42	NA	27%	NA	55	57
Amosova et al[19] 2011	Retrospective cohort	29	59 (5)	59 (6)	17	12	2	75	NA	NA	29 (100)	39%	NA	100	100
BEAUTIFUL[18] 2011	RCT	10917	65 (9)	65 (8)	5479	5438	19	72	24	23	9645 (88)	32%	NA	87	87
SHIFT[12] 2010	RCT	6505	61 (11)	60 (12)	3241	3264	23	80	52	52	3666 (56)	29%	8%	89	90

HR: Heart rate; RCT: Randomized controlled trial.